HERON THERAPEUTICS, INC. /DE/ Payments to Acquire Available-for-sale Securities
HERON THERAPEUTICS, INC. /DE/ (HRTX) reported Payments to Acquire Available-for-sale Securities of $127.76 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2019-05-09
- HERON THERAPEUTICS, INC. /DE/ payments to acquire available-for-sale securities for the quarter ending 2019-03-31 was $127.76M, a 224.37% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ payments to acquire available-for-sale securities for the quarter ending 2018-12-31 was $96.72M, a 248.00% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ payments to acquire available-for-sale securities for the quarter ending 2018-09-30 was $242.50M.
- HERON THERAPEUTICS, INC. /DE/ payments to acquire available-for-sale securities for the quarter ending 2018-06-30 was $118.50M, a 385.60% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ payments to acquire available-for-sale securities for fiscal 2018 was $497.10M, a 308.90% increase from fiscal 2017.
- HERON THERAPEUTICS, INC. /DE/ payments to acquire available-for-sale securities for fiscal 2017 was $121.57M, a 180.65% increase from fiscal 2016.
- HERON THERAPEUTICS, INC. /DE/ payments to acquire available-for-sale securities for fiscal 2016 was $43.32M, a 22.80% decline from fiscal 2015.
- HERON THERAPEUTICS, INC. /DE/ payments to acquire available-for-sale securities for fiscal 2015 was $56.12M.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2019-03-31 | $127.76M 10-Q · filed 2019-05-09 | $224.49M derived: sum of 2 quarters · filed 2019-05-09 | $466.98M derived: sum of 3 quarters · filed 2019-05-09 | $585.48M derived: sum of 4 quarters · filed 2019-05-09 |
| 2018-12-31 | $96.72M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $339.22M derived: sum of 2 quarters · filed 2019-02-22 | $457.72M derived: sum of 3 quarters · filed 2019-02-22 | $497.10M 10-K · filed 2019-02-22 |
| 2018-09-30 | $242.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $360.99M derived: sum of 2 quarters · filed 2018-11-07 | $400.38M 10-Q · filed 2018-11-07 | $428.18M derived: sum of 4 quarters · filed 2019-05-09 |
| 2018-06-30 | $118.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $157.88M 10-Q · filed 2018-08-08 | $185.68M derived: sum of 3 quarters · filed 2019-05-09 | $185.68M derived: sum of 4 quarters · filed 2019-05-09 |
| 2018-03-31 | $39.39M 10-Q · filed 2019-05-09 | $67.18M derived: sum of 2 quarters · filed 2019-05-09 | $67.18M derived: sum of 3 quarters · filed 2019-05-09 | $91.58M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $27.79M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $27.79M derived: sum of 2 quarters · filed 2019-02-22 | $52.20M derived: sum of 3 quarters · filed 2019-02-22 | $121.57M 10-K · filed 2019-02-22 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $24.40M derived: sum of 2 quarters · filed 2018-11-07 | $93.78M 10-Q · filed 2018-11-07 | $93.78M derived: sum of 4 quarters · filed 2019-02-22 |
| 2017-06-30 | $24.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $93.78M 10-Q · filed 2018-08-08 | $93.78M derived: sum of 3 quarters · filed 2019-02-22 | |
| 2017-03-31 | $69.37M 10-Q · filed 2018-05-10 | $69.37M derived: sum of 2 quarters · filed 2019-02-22 | ||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $43.32M 10-K · filed 2019-02-22 | ||
| 2016-09-30 | $43.32M 10-Q · filed 2017-11-06 | |||
| 2015-12-31 | $56.12M 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |